Nivolumab Therapy Prolongs Survival in Advanced Melanoma

MONDAY, Sept. 30, 2019 -- More patients with advanced melanoma receiving nivolumab plus ipilimumab or nivolumab alone have sustained long-term survival at five years compared with those receiving ipilimumab alone, according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news